Across ten studies of GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP) agonists, caloric intake was reduced by approximately 1639 % compared to placebo [16]
To be included, studies had to involve patients with a diagnosis of IIH according to established diagnostic (including modified Dandy or Friedman criteria) [16], administer a GLP-1 RA as an intervention, and report outcomes of interest such as ICP/CSF opening pressure, headache frequency/severity, visual function, weight/BMI, cognitive measures, and/or safety outcomes
Every meal delivers 35g+ protein in perfectly balanced portionsjust what your body needs to preserve lean mass on GLP-1s
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis
Na ltima dcada, passaram a ser aprovados tambm para obesidade
Its not a substitute for lifestyle changes